HERON THERAPEUTICS, INC. /DE/ — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
On August 7, 2026, Hercules Capital (lender) amended Heron's $110M+ working capital facility via a Fourth Amendment. Hercules waived minimum revenue and EBITDA covenants for June 30, 2026 test date, consented to an undisclosed strategic acquisition (redacted as '[***] Agreement'), and accepted a $13.5M mandatory prepayment plus $661.5K end-of-term charge. The lender also approved deferral of certain 2025 payments (via earlier amendments) at undisclosed rates. All dollar amounts and deal terms remain heavily redacted for competitive reasons.
Why this rating
Covenant waiver signals near-term cash/revenue weakness but represents ordinary covenant relief common in distressed biotech. Strategic deal approval is positive long-term. Relative to $235M market cap, $13.5M paydown is material (~6%) but manageable. Not trajectory-changing alone.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.